Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Sumanta K. Pal, MD, and Toni K. Choueiri, MD, on Urothelial Carcinoma: Efficacy of an FGFR Inhibitor

Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuss findings on BGJ398 in patients with previously treated advanced/metastatic urothelial carcinoma with FGFR3 alterations (Abstract 4517).

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Michael A. Postow, MD, on Results From the CheckMate 067 Melanoma Trial

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discuss findings from this phase III trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced disease (Abstract 9505).

Daniel F. Hayes, MD, ASCO President 2016–2017, on His Goals for the Coming Year

Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.

Gynecologic Cancers

The

Jonathan A. Ledermann, MD, and Ursula A. Matulonis, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer

Jonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discuss findings on overall survival in patients with platinum-sensitive relapsed serous ovarian cancer receiving olaparib maintenance monotherapy (Abstract 5501).

Prostate Cancer

Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies

Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).

Mar

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Sumanta K. Pal, MD, and Toni K. Choueiri, MD, on Urothelial Carcinoma: Efficacy of an FGFR Inhibitor

Anthony J. Olszanski, RPh, MD, and Michael A. Postow, MD, on Results From the CheckMate 067 Melanoma Trial

Daniel F. Hayes, MD, ASCO President 2016–2017, on His Goals for the Coming Year

Jonathan A. Ledermann, MD, and Ursula A. Matulonis, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer

Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies

Dynamic Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis

Pembrolizumab With or Without Lenvatinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AI Model for Predicting Oncotype DX 21-Gene Recurrence Score

Breast Cancer Recurrence Remains Low Even After 10 Years With Radiotherapy Tailored to Patient’s Individual Risk